Interlace Medical Inc. of Framingham has received clearance from the U.S. Food and Drug Administration to market a system for the removal of uterine polyps.
According to Interlace, its MyoSure Hysteroscopic Tissue Removal System allows doctors to quickly remove polyps and other uterine growths in one step without the use of “energy-based devices.”
Treatment with the Interlace system does not require an incision and preserves the form and function of the uterus.
Interlace is a medical device company focused on the treatment of gynecological diseases and conditions.
